Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Financial Select Sector SPDR Fund — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M), while Financial Select Sector SPDR Fund trades at $54.94 (market cap $51.80B). The key difference: Financial Select Sector SPDR Fund is far larger — about 53× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Financial Select Sector SPDR Fund is more actively traded (44,049,658 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| MRVI | XLF | |
|---|---|---|
Market Cap | $977.37M | $51.80B |
Volume | 2,742,564 | 44,049,658 |
Sector | Health | — |
52-Week High | $9.00 | $58.55 |
52-Week Low | $2.83 | $47.80 |
Typical Hold Time | 0 Days | 104 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
XLF trades at $54.82, down 0.42% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The ETF faces sector headwinds as financial stocks lag the broader market despite rising bank profits. Recent Federal Reserve stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The financial sector ETF benefits from rising interest rates but faces regulatory uncertainty and market underperformance risks. Key catalysts include Fed policy decisions and bank earnings, while political gridlock may limit legislative impacts on financial regulations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
